Skip to main content

Table 5 Subgroup analyses for the outcome of overall survival

From: Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

Subgroups

No. of studies

HR (95% CI)

I2 (P value)

Population

 Adult

4

1.15 (0.86–1.53)

0 (0.73)

 Children

3

2.40 (1.49–3.89)

37.7% (0.20)

 Mixed adult and children

3

3.06 (1.98–4.70)

32.1% (0.23)

Design

 Prospective

6

1.68 (1.02–2.77)

60.1% (0.03)

 Retrospective

4

2.37 (1.55–3.63)

64.8% (0.04)

Region

 Europe

5

2.05 (1.10–3.80)

83.0% (< 0.01)

 USA

3

2.10 (1.50–2.94)

1.8% (0.36)

 Asia

2

1.89 (0.99–3.62)

0 (0.32)

Detection method

 PCR

6

1.65 (1.07–2.55)

61.5% (0.02)

 FC

4

2.53 (1.58–4.04)

58.1% (0.07)

Adjustment

 Adjusted

4

2.58 (1.27–5.26)

71.1% (0.02)

 Crude

6

1.70 (1.18–2.44)

58.7% (0.03)